Literature DB >> 15139730

Integrated care pathways: disease-specific or process-specific?

Simon G M Edwards1, Alan J Thompson, E Diane Playford.   

Abstract

BACKGROUND/AIM: conventional teaching on integrated care pathways (ICP) suggests that they have to be specific both to a particular setting and to a specific diagnosis. We wished to explore the potential for a generic process-based care pathway. STUDY
DESIGN: we evaluated three different, disease-specific ICPs in use on a neurological rehabilitation unit to identify prompts common to and differing between them. Variance types and goal outcomes in all three diagnostic groups were compared.
RESULTS: 93% of prompts on the care pathway were common to all three diagnostic groups. The prompts that differed were unique to each diagnostic group and provided important guidelines about management.
CONCLUSION: in neurorehabilitation, where the process of multidisciplinary care is well defined, it is possible to develop a process-based ICP. Process-based ICPs may not be unique to rehabilitation but may also be relevant to other settings in which patients with differing diagnoses share similar needs.

Entities:  

Mesh:

Year:  2004        PMID: 15139730      PMCID: PMC4953998          DOI: 10.7861/clinmedicine.4-2-132

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  2 in total

1.  Should patients participate in clinical decision making? An optimised balance block design controlled study of goal setting in a rehabilitation unit.

Authors:  Rosaline C Holliday; Stefan Cano; Jennifer A Freeman; E Diane Playford
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

2.  Development of population-level colon cancer pathway concordance measures and association with survival.

Authors:  Luciano Ieraci; Maria Eberg; Katharina Forster; Paula M Murray; Emmett Borg; Steven Habbous; Ali Vahit Esensoy; Erin Kennedy; Claire M B Holloway
Journal:  Int J Cancer       Date:  2022-03-03       Impact factor: 7.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.